Global Anti-Fibrinolytic Drug Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Indication (Surgeries (Cardiac, Dental, Others), Menorrhagia, Hereditary Angioedema (HAE)), By Route Of Administration (Oral, Injection), By End User (Hospital And Clinics, Ambulatory Surgical Centers), And By Geography - Forecasts From 2022 To 2027

The global anti-fibrinolytic drug market is anticipated to grow at a CAGR of 9.48% to increase its market size from US$22.880 billion in 2020 to US$43.143 billion by 2027. 

Antifibrinolytics slow down the process of breaking down a blood clot. These drugs are majorly used to treat heavy menstrual bleeding and haemorrhages. Antifibrinolytic drugs are necessary to avert clot degradation in fibrinolysis-prone areas such as the nasal cavity, oral cavity, and female reproductive tract.

The rise in the number of surgeries around the globe is the primary driver of the global anti-fibrinolytic drug market.

These drugs are used in various surgeries, including cardiovascular and dental surgeries. Another factor that is fuelling the market growth of the global anti-fibrinolytic drug is the increasing number of road accidents. According to the World Health Organization (WHO), approximately 1.35 million people die annually from road traffic accidents. Also, road traffic injuries are the leading cause of death among children and young adults aged between 5 and 29 years. Since these drugs avert clot lysis and reduce blood loss, their demand is augmenting with an increasing number of road accidents and injuries, thus spurring the overall market growth.    

The growing global geriatric population contributes to market growth

According to the United Nations statistics, the number of people aged 60 years or above is projected to rise from 962.3 million in 2017 to 2080.5 million by 2050. The rising ageing population is boosting the demand for these drugs as the demographic shift towards an older population is putting a higher burden on various age-associated diseases worldwide. Factors such as increased life expectancy and declining fertility are the key factors behind the growing ageing population across the globe. Since it is challenging to keep the blood clot in case of surgery or any injury among this population group, the demand for anti-fibrinolytic drugs is escalating with the increasing number of older people worldwide.

Menstruation and Angioedema prevalence to increase the market size

Furthermore, these drugs are increasingly used by women to control heavy menstrual flow, which is also a prominent factor behind the growth of the global anti-fibrinolytic drug market. The growing prevalence of angioedema will continue to spur the global anti-fibrinolytic drug market growth during the forecast period. The availability of the anti-fibrinolytic drug in both oral and injection forms also contributes to the market growth of anti-fibrinolytic drugs to some extent. In July 2017, Zydus Cadila received the final approval from the U.S. Food and Drug Administration (FDA) to market Tranexamic Acid Injection, 1000mg/10mL single-dose vial. This medication is used to prevent or reduce bleeding in patients with haemophilia who require tooth extraction.

Market Segmentation for the anti-fibrinolytic drug market

The global anti-fibrinolytic drug market is segmented by indication, route of administration, end-user, and geography. Based on indication, the global anti-fibrinolytic drug market is segmented into surgeries (cardiac, dental, and others), menorrhagia, and hereditary angioedema (HAE). By route of administration, the global anti-fibrinolytic drug market segmentation is done as oral and injection. By end-user, the global anti-fibrinolytic drug market is segmented as hospitals and clinics and ambulatory surgical centres.

Increasing demand for anti-fibrinolytic drugs among women to treat menorrhagia

The prescribed anti-fibrinolytic drug market holds a noteworthy market share throughout the forecast period. The heavy menstrual bleeding segment accounted for a significant market share in 2019 and is poised to witness a prominent growth rate during the forecast period. A rise in the prevalence of menorrhagia among women forces them to visit gynaecologists to get prescribed anti-fibrinolytic drugs, thereby spurring overall market growth. Tranexamic acid (TXA) is the most widely used anti-fibrinolytic drug for this purpose. An increasing number of cardiac and brain surgeries will lead to the growth of the surgery segment during the forecast period.  

Hospitals and Clinics hold the larger market share

By end-user, hospitals and clinics segment dominates the global anti-fibrinolytic drug market as most of the surgeries take place in hospitals. With the increasing number of surgeries worldwide, the increased demand for these drugs in hospitals bolsters the global anti-fibrinolytic drug market growth during the forecast period.

By geography, North America holds a significant market share

Regionally, the global anti-fibrinolytic drug market is classified into North America, South America, Europe, the Middle East and Africa, and the Asia Pacific. North America accounted for a significant share of the global anti-fibrinolytic drug market in 2019. The presence of major pharmaceutical companies in the region contributes significantly to the notable share of this region in the global anti-fibrinolytic drug market. The growing adoption of anti-fibrinolytic drugs to control menstrual flow significantly contributes to the market growth of anti-fibrinolytic drugs in this region.

Moreover, a continuous rise in surgeries in countries like the U.S., Canada, and Mexico further augments the demand for anti-fibrinolytic drugs, thus positively impacting the regional market growth. According to the OECD (Organization for Economic Cooperation and Development) data, surgeries increased from 1,100,675 in 2011 to 1,182,649 in 2018. Similarly, in Mexico, the total number of surgeries surged from 6,57,730 in 2011 to 8,35,606 in 2018.

Asia Pacific (APAC) is projected to witness a substantial compound annual growth rate during the forecast period due to a surge in road traffic injuries and accidents. For example, in November 2019, according to a report by the Indian Ministry of Road Transport and Highways, the country witnessed a rise of 0.46 percent in total road accidents in 2018 compared to 2017. The rising focus among women on their health is also leading to the demand for anti-fibrinolytic drugs to control heavy menstrual flow, thus propelling the anti-fibrinolytic drug market growth in this region.

Key Developments

• May 2020: ORIAHNN®, a co-packaged oral estrogen and progestin combination medicine including elagolix, estradiol, and norethindrone acetate, has been given clearance by the U.S. Food and Drug Administration to treat premenopausal women's excessive monthly bleeding brought on by uterine leiomyomas (fibroids).

Impact of the COVID-19 pandemic on Anti-Fibrinolytic Drug Market

The COVID-19 pandemic led to a significant decline in industrial and commercial activity, owing to the strict government lockdown regulations. The healthcare sector was occupied with treating and controlling the spread of the virus, leaving other non-essential medical procedures. This led to a decline in surgeries and non-essential treatments and check-ups, resulting in a decline in demand for the anti-fibrinolytic drug market. According to the World Economic Forum, during the 12 weeks of the COVID-19 pandemic's peak interruption, 28 million elective procedures may have been postponed or canceled throughout the world. 38% of cancer surgeries worldwide were rescheduled or canceled. However, with the withdrawal of the COVID-19 lockdown protocols and the resumption of essential activities, the market is expected to be driven by a surge in medical procedures and surgeries, which were postponed during the pandemic. Hence, the market demand is anticipated to increase substantially.

Global Anti-Fibrinolytic Drug Market Scope:

Report Metric	Details
Market size value in 2020	US$22.880 billion
Market size value in 2027	US$43.143 billion
Growth Rate	CAGR of 9.48% from 2020 to 2027
Base year	2020
Forecast period	2022–2027
Forecast Unit (Value)	USD Billion
Segments covered	Indication, Route of Administration, End-User, And Geography
Regions covered	North America, South America, Europe, Middle East and Africa, Asia Pacific
Companies covered	Pfizer Canada ULC, Zydus Pharmaceuticals, Inc., Viatris Inc., Xanodyne Pharmaceuticals, Inc., American Regent, Inc. (Daiichi Sankyo Group)
Customization scope	Free report customization with purchase

 

Segmentation

• By Indication
  • Surgeries
    • Cardiac
    • Dental
    • Others
  • Menorrhagia
  • Hereditary Angioedema (HAE)
• By Route of Administration
  • Oral
  • Injection
• By End-User
  • Hospital and Clinics
  • Ambulatory Surgical Centers
• By Geography
  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • Israel
    • UAE
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Thailand
    • Indonesia
    • Others

---

Frequently Asked Questions (FAQs)

Q1. What will be the anti-fibrinolytic drug market size by 2027?
A1. The global anti-fibrinolytic drug market is anticipated to reach a market size of US$43.143 billion by 2027. 

Q2. What are the growth prospects for the anti-fibrinolytic drug market?
A2. The anti-fibrinolytic drug market is anticipated to grow at a CAGR of 9.48% during the forecast period. 

Q3. What is the size of the global anti-fibrinolytic drug market?
A3. Anti-Fibrinolytic Drug Market was valued at US$22.880 billion in 2020. 

Q4. What factors are anticipated to drive the anti-fibrinolytic drug market growth?
A4. The rise in the number of surgeries around the globe is the major driver of the global anti-fibrinolytic drug market.

Q5. Which region holds the largest market share in the anti-fibrinolytic drug market?
A5. North America holds a significant share in the anti-fibrinolytic drug market.

---